Get the Stockscreener App
2.92
2.01%
-0.06
After Hours:
2.89
-0.03
-1.03%
Tharimmune Inc stock is traded at $2.92, with a volume of 214.44K.
It is down -2.01% in the last 24 hours and down -7.01% over the past month.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
See More
Previous Close:
$2.98
Open:
$2.85
24h Volume:
214.44K
Relative Volume:
0.02
Market Cap:
$17.24M
Revenue:
-
Net Income/Loss:
$-9.32M
P/E Ratio:
-0.2297
EPS:
-12.7107
Net Cash Flow:
$-7.30M
1W Performance:
-3.63%
1M Performance:
-7.01%
6M Performance:
+153.91%
1Y Performance:
+46.89%
1-Day Range:
$2.78
$2.9993
1-Week Range:
$2.78
$3.52
52-Week Range:
$0.952
$9.08
Tharimmune Inc Stock (THAR) Company Profile
Name
Tharimmune Inc
Sector
Industry
Phone
302-743-2995
Address
1200 ROUTE 22 EAST, BRIDGEWATER
Compare THAR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
THAR
Tharimmune Inc
|
2.92 | 20.29M | 0 | -9.32M | -7.30M | -12.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Tharimmune Inc Stock (THAR) Latest News
Is Tharimmune Inc. still worth holding after the dipJuly 2025 Fed Impact & Community Verified Trade Signals - newser.com
Leading vs lagging indicators on Tharimmune Inc. performanceInsider Selling & Intraday High Probability Alerts - newser.com
Smart tools for monitoring Tharimmune Inc.’s price actionJuly 2025 WrapUp & Long-Term Safe Return Strategies - newser.com
Measuring Tharimmune Inc.’s beta against major indicesJuly 2025 Decliners & Fast Gaining Stock Strategy Reports - newser.com
Volume spikes in Tharimmune Inc. stock – what they mean2025 Key Lessons & Capital Efficiency Focused Strategies - newser.com
Is now a turning point for Tharimmune Inc.Market Sentiment Review & Free Technical Pattern Based Buy Signals - newser.com
Tharimmune increases authorized common shares to 1 billion By Investing.com - Investing.com Nigeria
Tharimmune Increases Authorized Shares to 1 Billion - TipRanks
Tharimmune Stockholders Approve Key Strategic Proposals - TipRanks
Can volume confirm reversal in Tharimmune Inc.Weekly Investment Report & Entry Point Confirmation Signals - newser.com
Weiss Ratings Reaffirms Sell (E+) Rating for Tharimmune (NASDAQ:THAR) - Defense World
What analysts say about Tharimmune Inc stockShort Selling Opportunities & Exceptional Profit Growth - earlytimes.in
Tharimmune Inc Stock Analysis and ForecastOptions Trading Strategies & Affordable Trading Strategies - earlytimes.in
Candlestick signals on Tharimmune Inc. stock todayTrade Exit Summary & Reliable Intraday Trade Alerts - newser.com
Tharimmune Amends Warrants Agreement to Boost Liquidity - TipRanks
Tharimmune amends warrants to make 3.4 million shares immediately exercisable - Investing.com
Analyzing recovery setups for Tharimmune Inc. investorsMarket Weekly Review & Fast Exit/Entry Strategy Plans - newser.com
Tick level data insight on Tharimmune Inc. volatilityJuly 2025 Momentum & Free Fast Entry Momentum Trade Alerts - newser.com
What does recent volatility data suggest for Tharimmune Inc.Gap Down & Comprehensive Market Scan Insights - newser.com
Why Tharimmune Inc. is moving todayWeekly Gains Summary & Safe Entry Point Identification - newser.com
Wall Street Zen Upgrades Tharimmune (NASDAQ:THAR) to Hold - Defense World
Tharimmune (NASDAQ:THAR) Trading Down 2.1% – What’s Next? - Defense World
Pleasing Signs As A Number Of Insiders Buy Tharimmune Stock - Yahoo Finance
Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl - El Paso Times
Is Tharimmune Inc a good long term investmentRisk Adjusted Returns & Capital Efficiency Improvement - earlytimes.in
Published on: 2025-09-27 14:56:49 - newser.com
Tharimmune Inc Stock (THAR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):